Sensei Biotherapeutics, Inc. financial data

Symbol
SNSE on Nasdaq
Industry
Pharmaceutical Preparations
Location
1405 Research Blvd, Suite 125, Rockville, MD
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 980 % -24.2%
Debt-to-equity 15.5 % +10.5%
Return On Equity -61.9 % -40.7%
Return On Assets -53.6 % -38.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.2M shares +0.51%
Common Stock, Shares, Outstanding 25.2M shares +0.6%
Entity Public Float 10.3M USD -44.9%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 25.1M shares -10.1%
Weighted Average Number of Shares Outstanding, Diluted 25.1M shares -10.1%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 13M USD -30.5%
Operating Income (Loss) -32.6M USD +12%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -30.2M USD +11.6%
Earnings Per Share, Basic -1.2 USD/shares +1.64%
Earnings Per Share, Diluted -1.2 USD/shares +1.64%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.99M USD -23.2%
Other Assets, Current 120K USD -63.1%
Assets, Current 41.9M USD -37.7%
Property, Plant and Equipment, Net 417K USD -64.2%
Operating Lease, Right-of-Use Asset 2.8M USD -35.2%
Other Assets, Noncurrent 48K USD -44.2%
Assets 45.4M USD -39%
Accounts Payable, Current 244K USD -57.4%
Employee-related Liabilities, Current 1.88M USD +24.6%
Accrued Liabilities, Current 847K USD -5.89%
Liabilities, Current 5.45M USD -3.46%
Operating Lease, Liability, Noncurrent 1.43M USD -52.4%
Other Liabilities, Noncurrent 67K USD -6.94%
Liabilities 6.98M USD -26.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -13K USD +93.8%
Retained Earnings (Accumulated Deficit) -262M USD -13%
Stockholders' Equity Attributable to Parent 38.4M USD -40.8%
Liabilities and Equity 45.4M USD -39%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.62M USD +35.1%
Net Cash Provided by (Used in) Financing Activities -209K USD +20.2%
Net Cash Provided by (Used in) Investing Activities 5.77M USD +150%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 25.2M shares +0.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.06M USD +78.8%
Deferred Tax Assets, Valuation Allowance 58.2M USD +14%
Deferred Tax Assets, Gross 59M USD +12.1%
Operating Lease, Liability 3.02M USD -34%
Payments to Acquire Property, Plant, and Equipment 37K USD -75.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -30M USD +10%
Lessee, Operating Lease, Liability, to be Paid 3.22M USD -36.4%
Property, Plant and Equipment, Gross 1.91M USD -33.9%
Operating Lease, Liability, Current 1.59M USD +1.21%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.41M USD -18.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.75M USD -5.67%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 205K USD -58.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 59K USD -95.8%
Deferred Tax Assets, Operating Loss Carryforwards 37M USD +11.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 59K USD -95.8%
Operating Lease, Payments 462K USD +12.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 551K USD -3.5%
Deferred Tax Assets, Net of Valuation Allowance 848K USD -47.8%
Share-based Payment Arrangement, Expense 3.14M USD -29.6%
Interest Expense 90K USD -37.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%